ArticleCell death & disease2018

Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer.

Eya Wolfson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.